1 / 10

Dyslipidemia Drugs Market Expected to Reach USD 6.9 Billion Globally in 2023

Global Dyslipidemia Drugs Market was valued at USD 17.9 billion in 2014 and is estimated to reach a market worth of USD 6.9 billion in 2023 growing at a CAGR of -10.3% from 2015 to 2023.

kksingha
Télécharger la présentation

Dyslipidemia Drugs Market Expected to Reach USD 6.9 Billion Globally in 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Dyslipidemia Drugs Market:Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 Published Date 05-Aug-2015 101 Page Report Request Sample Buy Now Press Release Dyslipidemia Drugs Market Expected to Reach USD 6.9 Billion Globally in 2023:Transparency Market Research Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Dyslipidemia Drugs Market REPORT DESCRIPTION Dyslipidemia Drugs Market:Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 The occurrence of cholesterol abnormalities has been on the rise for the past few years – the occurrence of dyslipidemia, a chronic metabolic syndrome, characterized by an increase in the level of plasma triglycerides, a dip in levels of lipoproteins as well as low-density lipoprotein composition. Given the progressive rise in the burden of dyslipidemia on healthcare agencies because of its high mortality and morbidity rate, healthcare agencies are relying on drugs to bring dyslipidemia under control. This factor will stimulate growth in an otherwise dull outlook for the global dyslipidemia market. According to the findings of a recent research report published by Transparency Market Research, the global dyslipidemia market will post a negative CAGR of -10.3% between 2015 and 2023. Contracting at this rate, the market, which was worth US$17,858.3 million will slide down to an estimated USD 6,888.9 million by the end of 2023. Browse Full Report With TOC: http://www.transparencymarketresearch.com/dyslipidemia-market.html Statins are Leading Drug Class in Global Dyslipidemia Market but Decline of Niacins Market to Hamper Overall Growth If the global dyslipidemia market were to be segmented on the basis of drug type, it is possible to create the following segments: Statins, fibric acid and omega-3 fatty acid derivatives, bile acid resins, niacins, and others. As evidenced by various market research reports, the high efficacy of statins makes them the leading drug type within the global dyslipidemia market. In 2014, the statins market held over 59.3% of the overall dyslipidemia market globally. However, the dyslipidemia market’s growth will be severely curtailed by the steep decline in the sales of Niaspin from Abbott Laboratories. It is easy to see thus, that the severe downward trend in the niacins market will have a detrimental impact on the overall dyslipidemia market as well. Report Press Release: http://www.transparencymarketresearch.com/pressrelease/dyslipidemia-market.htm Germany Shines in Global Dyslipidemia Drugs Market Even as North America and Europe Lead Globally The outlook of the dyslipidemia market in Germany remains positive, despite the fact that the global market’s scenario looks uninspiring. From the regional markets perspective, North America was the leader in the global dyslipidemia market as of 2014, with Europe in second place. Germany was the largest national market, contributing substantially to Europe’s dominant position. In Germany, the prevalence rate of dyslipidemia remains high. At the same time, the demand for drug therapies to treat dyslipidemia is Europe held a share of 25% of the total dyslipidemia market in 2014. 2 Transparency Market Research

  3. Anxiety Disorder And Depression Market Factors driving the North American and European dyslipidemia drugs market are similar – more consumers here can afford branded drug formulations (as compared to their counterparts in other developing regions) and drug approval policies remain positive in the overall dyslipidemia market. Opportunity Alert: Biological Therapies for Treating Dyslipidemia Although growth in the dyslipidemia market is expected to remain lackluster, there are a few opportunities that can potentially open up hitherto untapped growth opportunities for regional and global players. With a growing interest in biological therapies, thanks to their proven efficiency, there is considerable scope for R&D pertaining to novel molecules, especially from a newer class of dyslipidemia drugs. The other opportunity lies in collaborative drug development projects in order to create a new avenues for growth, especially in the developing dyslipidemia drugs markets. Browse Article:http://www.transparencymarketresearch.com/article/dyslipidemia-market.htm Table Of Contents Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Sources 1.3.1.1 Secondary Research 1.3.1.2 Primary Research 1.3.1.3 Assumption 1.4 List of Abbreviations Chapter 2 Executive Summary 2.1 Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023) 2.2 Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million) 2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %) Chapter 3 Market Overview 3 Transparency Market Research

  4. Anxiety Disorder And Depression Market 3.1 Overview 3.2 Epidemiology: Dyslipidemia 3.3 Etiology of Dyslipidemia 3.3.1 Primary Causes (genetic causes of dyslipidemia) 3.3.2 Secondary Causes (lifestyle factors) 3.4 Dyslipidemia Diagnostics 3.4.1 Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.) 3.4.2 Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.) 3.4.3 Secondary Causes Screening and Diagnostics 3.5 Trends and Future Aspects in Dyslipidemia Therapeutics (e.g. PCSK9, CETP inhibitors, etc.) 3.6 Market Dynamics 3.6.1 Market Drivers 3.6.1.1 Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market 3.6.1.2 Rise in obese and diabetic populations is expected to increase the incidence of dyslipidemia, and thus demand for dyslipidemia drugs 3.6.1.3 Extensive research and development changes bring turnaround changes in the dyslipidemia drugs market 3.6.1.4 Rising disease awareness through promotional activities 3.6.2 Market Restraints 3.6.2.1 Impending patent expirations to deplete profit margins 3.6.2.2 Discontinuation of novel dyslipidemia drugs 3.6.3 Opportunities 3.6.3.1 Expanding footprint in emerging nations to generate high sales growth 3.6.3.2 Biological therapies for the treatment of dyslipidemia 3.6.3.3 Development of molecules from newer class of dyslipidemia drugs provide a ladder for growth 3.6.3.4 Strategic collaborations for new drug development 3.7 Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography 3.8 Market Share by Key Players of Global Dyslipidemia Drugs Market, 2014 (Value %) 4 Transparency Market Research

  5. Anxiety Disorder And Depression Market 3.8.1 Global Dyslipidemia Drugs Market Share Analysis, by Key Players, 2014 (%) Chapter 4 Dyslipidemia Drugs Market, by Drug Class 4.1 Introduction 4.1.1 Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 – 2023 (USD Million) 4.2 Statins 4.2.1 Statins Market Revenue, 2013 – 2023 (USD Million) 4.3 Bile Acid Resins (Cholestyramine, Colestipol, Colesevelam, etc.) 4.3.1 Bile Acid Resins Market Revenue, 2013 – 2023 (USD Million) 4.4 Fibric Acid and Omega-3 Fatty Acid Derivatives (Fenofibrate, Gemfibrozil, Vascespa, etc.) 4.4.1 Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 – 2023 (USD Million) 4.5 Niacins (Niacor, Niaspan, Slo-Niacin, etc.) 4.5.1 Niacins Market Revenue, 2013 – 2023 (USD Million) 4.6 Others (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors, etc.) 4.6.1 Others Market Revenue, 2013 – 2023 (USD Million) 4.7 Pipeline Drugs 4.7.1 Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 – 2023 (USD Million) 4.7.2 Anacetrapib (MK-0859) 4.7.2.1 Anacetrapib Market Revenue, 2018 – 2023 (USD Million) 4.7.3 Evacetrapib (LY2484595) 4.7.3.1 Evacetrapib Market Revenue, 2017 – 2023 (USD Million) 4.7.4 Praluent (Alirocumab) 4.7.4.1 Praluent Market Revenue, 2015 – 2023 (USD Million) 4.7.5 Evolocumab (Repatha) 4.7.5.1 Evolocumab Market Revenue, 2015 – 2023 (USD Million) 4.7.6 Bococizumab (RN316) 4.7.6.1 Bococizumab Market Revenue, 2019 – 2023 (USD Million) 5 Transparency Market Research

  6. Anxiety Disorder And Depression Market Chapter 5 Dyslipidemia Drugs Market, by Geography 5.1 Overview 5.1.1 Dyslipidemia Drugs Market Revenue, by Geography, 2013 – 2023 (USD Million) 5.2 North America 5.2.1 North America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million) 5.3 Europe 5.3.1 Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million) 5.4 Asia Pacific 5.4.1 Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million) 5.5 Latin America 5.5.1 Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million) 5.6 Middle East and Africa 5.6.1 Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 – 2023 (USD Million) Chapter 6 Recommendations 6.1 Developing combination drugs for the treatment of dyslipidemia 6.2 Major research-based drug developing companies must collaborate with hospitals or acquire pharma establishments to develop more effective dyslipidemia treatments 6.3 Global players should target low to medium income countries to generate higher revenues Chapter 7 Company Profiles 7.1 Abbott Laboratories 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 AstraZeneca plc 7.2.1 Company Overview 6 Transparency Market Research

  7. Anxiety Disorder And Depression Market 7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 Amgen, Inc. 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Bayer AG 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Bristol-Myers Squibb Company 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments 7.6 Mylan N.V. 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7 Transparency Market Research

  8. Anxiety Disorder And Depression Market 7.7 Novartis AG 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments 7.8 Merck & Co., Inc. 7.8.1 Company Overview 7.8.2 Financial Overview 7.8.3 Product Portfolio 7.8.4 Business Strategies 7.8.5 Recent Developments 7.9 Pfizer, Inc. 7.9.1 Company Overview 7.9.2 Financial Overview 7.9.3 Product Portfolio 7.9.4 Business Strategies 7.9.5 Recent Developments 7.10 Shionogi & Co., Ltd. 7.10.1 Company Overview 7.10.2 Financial Overview 7.10.3 Product Portfolio 7.10.4 Business Strategies 7.10.5 Recent Developments 7.11 Takeda Pharmaceutical Company Limited 7.11.1 Company Overview 7.11.2 Financial Overview 7.11.3 Product Portfolio 8 Transparency Market Research

  9. Anxiety Disorder And Depression Market 7.11.4 Business Strategies 7.11.5 Recent Developments 7.12 Teva Pharmaceutical Industries Ltd. 7.12.1 Company Overview 7.12.2 Financial Overview 7.12.3 Product Portfolio 7.12.4 Business Strategies 7.12.5 Recent Developments Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=1535 Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 9 Transparency Market Research

  10. Anxiety Disorder And Depression Market Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : https://herepharmablog.wordpress.com 10 Transparency Market Research

More Related